Table 10.

Impact of resveratrol on the expression of genes in the context of other cancers

Type of cancer	Dose range	Cell line	Target	Pathway	Function	Refs.
In vivo studies
Breast cancer (BCa)	50 mg/kg, 10–200 mg/L	MCF-7/DOX, MCF-7, MDA-MB-231	Caspase-3, P70S6K	PI3K/AKT/mTOR	RVT via inhibiting PI3K/AKT/ mTOR pathway could play a role in DOX resistance in breast neoplasm	[90]
Papillary Thyroid cancer (PTC)	30 mg/kg 50 μM	KTC-1,TPC-1	Caspase-3/8/9, Bax, Bcl-xl, Mcl-1, p70S6K	PI3K/AKT/mTOR	RVT via the PI3K/AKT/mTOR pathway could promote the anti-tumor effects of rapamycin in papillary thyroid cancer	[89]
Glioblastoma multiforme (GBM)	10 mg/kg, 0–20 μM	GICs	IKKα/β, JNK, mTOR, ERK1/2, IκBα p38, MMP-2, Lamin-A, Nestin, GFAP	PI3K/ AKT/NF-κB	RVT via downregulating PI3K/AKT/NF-κB pathway could inhibit invasion of glioblastoma-initiating cells (GICs)	[91]
In vitro studies
Melanoma	4 μM-18 μM	Human melanoma cell	–	AKT	RVT via dephosphorylation of AKT could overcome resistance to vemurafenib in BRAF-mutated melanoma cells	[86]
Melanoma	100 μM	B16	LC3-l, LC3-ll, Beclin-1, S6K, 4E-BP1	Ceramide/AKT/mTOR	RVT via the ceramide/AKT/mTOR pathway could trigger protective autophagy in melanoma B16 cells	[87]
Melanoma	0–100 μM	B16-F10, A375	Beclin-1, Caspase-9, P62, LC3II/I	PI3K/ AKT/mTOR	RVT via inhibiting the PI3K/AKT/mTOR pathway could promote autophagy and suppress melanoma growth	[92]
Pheochromocytoma	10–1000 μM	PC12	Caspase-3, iNOS	PI3K, AKT/p38 MAPK	RVT via AKT/p38 MAPK signaling could attenuate apoptosis, and protect neuronal cells from isoflurane-induced inflammation	[93]
BCa	10–25 μM	SK-BR-3, MCF7, T47D, MDA-MB-231	Caspase-7/8, JNK, P38, XIAP, Survivin, Bcl-2	AKT, HER-2, MAPK	RVT via inhibiting docetaxel-mediated activation of the HER-2/AKT axis could sensitize BCa cells to docetaxel-induced cytotoxicity	[88]
Bladder cancer	0–50 μmol/L	T24, 5637, SV-HUC-1	miR-21, Bcl-2, Caspase-3	AKT	RVT via miR-21 regulation of the AKT/Bcl-2 pathway could induce apoptosis of bladder cancer cells	[94]
Chondrosarcoma	25–100 μM	JJ012, SW1353	MMP2, MMP9	PI3K/AKT/MAPK	RVT via regulating the PI3K/AKT/MAPK pathway could inhibit cell proliferation and induce cell apoptosis in chondrosarcoma cells	[95]
Renal cell carcinoma (RCC)	0–100 μM	ACHN, A498, HK-2	N-cadherin, Vimentin, Snail, MMP-2/9, E-cadherin, TIMP-1	AKT, ERK1/2	RVT via inactivating the AKT and ERK1/2 pathways could inhibit proliferation and migration in RCC cells	[96]
Oral cancer	50 μM	CAR, CAL 27	LC3-II/I, Caspase-3/9, Atg-5/7/12/14, Beclin-1, Atg16L1, Apaf-1, AIF, Bcl-2, Bax, Bad	AKT/mTOR, AMPK	RVT via the AMPK and AKT/mTOR pathway could regulate autophagy and apoptosis in cisplatin-resistant human oral cancer CAR cells	[97]
Neuroblastoma (NB)	10–100 μM	SK-N-SH, SH-SY5Y, SK-N-Be2, SMS-KCNR, NB1691	GSK3β, IRS-1, Survivin, PP1α, α-tubulin	AKT	RVT via inactivating AKT by increasing PP1α activity could potentiate 2-DG-induced ER stress and NB cell death	[98]